首页> 外文期刊>Gastrointestinal Endoscopy >Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy.
【24h】

Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy.

机译:前列腺素预防非甾体类抗炎药引起的小肠损伤:通过胶囊内窥镜评估的一项试验性随机对照试验。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: There is no known preventive agent against nonsteroidal anti-inflammatory drug (NSAID) induced small-intestinal injury. OBJECTIVE: To evaluate by capsule endoscopy whether coadministration of prostaglandin (PG) can prevent small-intestinal damage induced by short-term NSAID treatment. DESIGN: Single-blind, randomized, controlled trial. SETTING: All procedures were performed at Nippon Medical School. SUBJECTS: Thirty-four healthy male volunteers. METHODS: All subjects were randomly assigned to 2 groups: an NSAID-control group, who underwent NSAID (diclofenac sodium, 25 mg 3 times daily) and omeprazole (20 mg once daily) treatment, and an NSAID-PG group, who received PG (misoprostol, 200 microg 3 times daily) in addition to the same NSAID-omeprazole treatment. Eligible subjects, 15 per group, underwent capsule endoscopy before and 14 days after treatment. MAIN OUTCOME MEASUREMENTS: The number of mucosal breaks at capsule endoscopy. RESULTS: NSAID treatment significantly increased the mean (SD) number of mucosal breaks per subject, from a basal level of 0.1 +/- 0.3 up to 2.9 +/- 6.3 lesions in the NSAID-control group (P = .012). In contrast, there was no significant change in the mean number of mucosal breaks before and after PG cotreatment (P = 0.42). Thus, the mean number of posttreatment mucosal breaks per subject was significantly higher in the NSAID-control group than in the NSAID-PG group (P = .028). There was a significant increase in the percentage of subjects in the NSAID-control group, with at least 1 mucosal break after treatment (from 6.7% to 53.3%), whereas there was no change in the incidence of mucosal breaks in the NSAID-PG group, which remained at 13.3%. (P = .002). LIMITATIONS: Single-center, open-label study. CONCLUSIONS: PG cotherapy reduced the incidence of small-intestinal lesions induced by a 2-week administration of diclofenac sodium.
机译:背景:尚无针对非甾体抗炎药(NSAID)引起的小肠损伤的预防剂。目的:通过胶囊内窥镜检查评估联合使用前列腺素(PG)是否可以预防短期NSAID治疗引起的小肠损伤。设计:单盲,随机,对照试验。地点:所有程序均在日本医学院进行。受试者:34名健康男性志愿者。方法:将所有受试者随机分为2组:NSAID对照组,接受NSAID(双氯芬酸钠,每天3次,每次25 mg)和奥美拉唑(每天,一次,每次20 mg),NSAID-PG组,接受PG。 (米索前列醇,每日200次,每日3次),同时进行NSAID-奥美拉唑治疗。符合条件的受试者(每组15人)在治疗前和治疗后14天接受胶囊内镜检查。主要观察指标:胶囊内镜检查时粘膜破裂的次数。结果:NSAID治疗显着增加了每名受试者的平均粘膜断裂次数(SD),从基础水平的0.1 +/- 0.3上升至2.9 +/- 6.3病变(NSAID对照组)(P = 0.012)。相比之下,PG联合治疗前后平均粘膜破裂次数没有显着变化(P = 0.42)。因此,在NSAID对照组中,每名受试者的平均治疗后粘膜断裂次数明显高于NSAID-PG组(P = .028)。 NSAID对照组的受试者百分比显着增加,治疗后至少1次粘膜破裂(从6.7%到53.3%),而NSAID-PG中粘膜破裂的发生率没有变化组,仍然保持在13.3%。 (P = .002)。局限性:单中心,开放标签的研究。结论:PG联合疗法可降低双氯芬酸钠2周给药引起的小肠病变的发生率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号